Compugen Ltd. (TLV:CGEN)

Market Cap	468.51M
Revenue (ttm)	74.61M
Net Income (ttm)	-65.24M
Shares Out	n/a
EPS (ttm)	-0.72
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	29,567
Average Volume	103,683
Open	503.20
Previous Close	503.20
Day's Range	484.30 - 508.50
52-Week Range	442.80 - 950.00
Beta	2.62
RSI	41.91
Earnings Date	Aug 6, 2025

About Silk Road Medical

Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company’s pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/T...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1993
• Employees: 74
• Stock Exchange: Tel Aviv Stock Exchange
• Ticker Symbol: CGEN

Financial Performance

In 2024, Compugen's revenue was $27.86 million, a decrease of -16.72% compared to the previous year's $33.46 million. Losses were -$14.23 million, -24.12% less than in 2023.